Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H β-synuclein

Neuroscience Letters

Volumn 515, Issue 1, 2012, Pages 97-101

  Sekiyama, Kazunari ^a   Fujita, Masayo ^a   Sekigawa, Akio ^a   Takamatsu, Yoshiki ^a   Waragai, Masaaki ^a   Takenouchi, Takato ^b   Sugama, Shuei ^c   Hashimoto, Makoto ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Synuclein; Alzheimer's disease; Dementia with lewy bodies; Ibuprofen; Parkinson's disease; Transgenic mouse

Indexed keywords

BETA SYNUCLEIN; IBUPROFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG EFFECT; HISTOPATHOLOGY; LEARNING DISORDER; MALE; MAZE TEST; MORRIS WATER MAZE TEST; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; THERAPY EFFECT; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; BETA-SYNUCLEIN; COGNITION DISORDERS; GENE EXPRESSION REGULATION; GLIOSIS; IBUPROFEN; LEWY BODIES; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC;

EID: 84859441155     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.03.037     Document Type: Article

References (17)

1. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A.AT Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Ann. Neurol. 2005, 58(6):963-967.
2. Fujita M., Sugama S., Sekiyama K., Sekigawa A., Tsukui T., Nakai M., Waragai M., Takenouchi T., Takamatsu Y., Wei J., Rockenstein E., Laspada A.R., Masliah E., Inoue S., Hashimoto M. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat. Commun. 2010, 1:110.
3. Hashimoto M., Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999, 9(4):707-720.
4. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001, 32(2):213-223.
5. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345(21):1515-1521.
6. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 2001, 22(6):983-991.
7. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Hsiao Ashe K., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20(15):5709-5714.
8. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
9. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V., Lee V.M., Trojanowski J.Q., Ishikawa A., Idezuka J., Murata M., Toda T., Bird T.D., Leverenz J.B., Tsuji S., La Spada A.R. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63(5):805-811.
10. Robinson J.L., Geser F., Corrada M.M., Berlau D.J., Arnold S.E., Lee V.M., Kawas C.H., Trojanowsk J.Q. Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain 2011, 134(Pt 12):3705-3712.
11. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37(4):583-595.
12. Trojanowski J.Q., Goedert M., Iwatsubo T., Lee V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 1998, 5(10):832-837.
13. Ubhi K., Peng K., Lessig S., Estrella J., Adame A., Galasko D., Salmon D.P., Hansen L.A., Kawas C.H., Masliah E. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neurosci. Lett. 2010, 485(3):222-227.
14. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414(6860):212-216.
15. Wei J., Fujita M., Nakai M., Waragai M., Sekigawa A., Sugama S., Takenouchi T., Masliah E., Hashimoto M. Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. J. Biol. Chem. 2007, 282(39):28904-28914.
16. Wei J., Fujita M., Nakai M., Waragai M., Watabe K., Akatsu H., Rockenstein E., Masliah E., Hashimoto M. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am. J. Pathol. 2009, 174(5):1891-1909.
17. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23(20):7504-7509.